Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iNOS shRNA
- Development stage
- Preclinical
- Lead developer
- Instituto de Oncologia Angel H. Roffo
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
iNOS shRNA is an experimental RNA interference (RNAi) agent designed to silence the expression of inducible nitric oxide synthase (iNOS, also known as NOS2). In the context of oncology research, specifically bladder cancer, iNOS shRNA is used to investigate the role of endogenous nitric oxide (NO) generation in the maintenance and self-renewal of cancer stem cells (CSCs). By targeting and degrading iNOS mRNA, the shRNA reduces iNOS protein levels and subsequent NO production. Preclinical studies in murine models have demonstrated that silencing iNOS leads to a decrease in sphere-forming efficiency and the downregulation of stemness-related genes such as Sox2, Oct4, and Nanog, thereby inhibiting tumor growth and recurrence. This approach is currently utilized as a research tool to validate iNOS as a potential therapeutic target for eradicating CSC populations responsible for disease relapse.
- Other names
- shiNOSNOS2 shRNANOS-2 shRNANOS 2 shRNAinducible nitric oxide synthase short hairpin RNA
02
Targets
NOS2 (Nitric Oxide Synthase 2)
Beyond the preview
Go deeper on iNOS shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iNOS shRNA.